FDA Grants Profounda Inc. Orphan Drug Designation for treatment of Granulomatous Amebic Encephalitis
- GAE is a serious infection of the brain and spinal cord that typically occurs in persons with a compromised immune system. - Few patients are known to have survived because of successful drug treatment. Early diagnosis and treatment might increase the chances for survival. ORLANDO, Fla., June. 29, 2017 /PRNewswire/ -- Profounda, Inc. ("Profounda") announced today that it has received the US Food and Drug Administration's Orphan Drug Designation for the use of miltefosine to
